BB Biotech’s NAV rose 5.6% in CHF in Q3 2026 and the share price 6.5%, trailing the Nasdaq Biotech Index (NBI), which gained 12.0%. The index advance was unusually narrow, led by a handful of constituents outside BB Biotech’s therapeutics focus. The share price nevertheless outperformed NAV, and the discount narrowed from 12.9% to 12.2%.
LÄS MER
